Right Drug Dose Now Act of 2024
Latest Action
Referred to the House Committee on Energy and Commerce.
Official Summary
Official summary has not been imported yet.
GovScope Watchdog™
AI Government Intelligence™The Right Drug Dose Now Act of 2024 is a health-related bill introduced in the 118th Congress, House of Representatives, aimed at addressing issues related to drug dosing. The bill was referred to the House Committee on Energy and Commerce on March 29, 2024. However, no official summary or full text of the bill is publicly available, and the bill status is recorded as Failed / Expired. Due to the lack of detailed information, specific provisions, goals, or mechanisms of the bill cannot be described.
This bill intended to address drug dosing issues but lacks publicly available details and did not advance beyond committee referral before expiring.
- The bill is titled the Right Drug Dose Now Act of 2024 and relates to health policy.
- It was introduced in the House during the 118th Congress and referred to the House Committee on Energy and Commerce.
- The bill did not progress and is marked as Failed / Expired with no publicly available full text or summary.
['Potential beneficiaries could include patients requiring accurate drug dosing, healthcare providers, and health agencies involved in medication safety, though specifics are not available.']
['Without the full text or summary, it is unclear what implementation challenges, costs, or oversight mechanisms the bill proposed.', 'The absence of detailed provisions limits assessment of authority delegation or policy tradeoffs.']
The bill was introduced in the 118th Congress and referred to the House Committee on Energy and Commerce, a common committee for health-related legislation. Its failure to advance suggests it did not gain sufficient legislative support or priority during the session.
Hidden impact flags detected: 2
GovScope reviewed 2 policy-risk categories. Hover for a quick definition. Click detected flags for bill-specific details.
['If enacted, the bill could have influenced healthcare practices related to drug dosing, potentially impacting patient safety and healthcare provider protocols.', 'Failure to pass may delay or prevent reforms in drug dosing standards or regulations.']
The absence of publicly available bill text and summary limits transparency and public scrutiny. The bill's failure to advance beyond committee referral highlights the importance of tracking legislative progress to understand which proposals receive further consideration. Monitoring similar future bills could provide insights into evolving health policy priorities.
GovScope Intelligence Roadmap
Future bill intelligence will connect sponsors, committee referrals, related votes, campaign finance, disclosures, and stock trades into one legislative intelligence view.